Michael R. Jaff Named to HeartBeam’s Board of Directors

HeartBeam Inc. has appointed Michael R. Jaff, D.O., to its Board of Directors. The appointment brings the number of HeartBeam board members to eight.

“We are thrilled to have Dr. Jaff join our board,” HeartBeam Founder/CEO Branislav Vajdic, Ph.D., said. “He adds a unique and extremely valuable perspective that is crucial for HeartBeam as we progress toward our initial clearances and the commercial availability of our technology. The company will benefit from having the guidance of Dr. Jaff, along with recent additions Ken Nelson and Mark Strome, at this exciting time.”

“Dr. Jaff brings an extraordinary level of expertise to the HeartBeam board, with his extensive experience as a researcher, practicing clinician, hospital administrator, and industry executive,” HeartBeam Executive Chairman Rich Ferrari added. “His knowledge in clinical trial design and execution, as well as his experience supporting novel technologies in front of the U.S. Food and Drug Administration, will be valuable for the company.”
 
Jaff is chief medical officer and vice president of Clinical Affairs, Technology, and Innovation of the Peripheral Interventions division at Boston Scientific Corporation. Previously, he was a professor of medicine at Harvard Medical School and was president of Newton-Wellesley Hospital. Prior to that, Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and medical director of the Fireman Vascular Center at the Massachusetts General Hospital. He is a recognized expert in all aspects of vascular medicine and is the founder of VasCore, the Vascular Ultrasound Core Laboratory. Jaff has published more than 300 peer-reviewed publications and 10 textbooks and is the past president of the Society for Vascular Medicine.
 
“I am passionate about innovation in health care and am excited to join the board at HeartBeam,” Jaff stated. “Their technology has the potential to bring standard of care cardiac diagnostic technology directly to patients, improving outcomes and saving lives while reducing unnecessary expenditures. I look forward to contributing to these efforts.”
 
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and clinicians to assess cardiac symptoms quickly and easily. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.

HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies.